Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.52 |
| ▸ | F2 | P00734 | 4/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 1/20 | 0.47 |
| ▸ | SCTR | P47872 | 1/20 | 0.47 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30710208 | 0.93 | NPY4R (0.51) | F2NPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL31345046 | 0.89 | BACE1 (0.53) | BACE1BACE2F2NPY1RNPY2R | |
| SCHEMBL30927574 | 0.89 | NPY1R (0.50) | F2NPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29591602 | 0.88 | NAALAD2 (0.48) | BACE1BACE2F2NPY1RNPY2R | |
| SCHEMBL29496487 | 0.88 | F2 (0.53) | BACE1BACE2F2GLP1RKISS1R | |
| SCHEMBL29630791 | 0.87 | NAALAD2 (0.49) | BACE1BACE2F2NPY1RNPY2R | |
| SCHEMBL31410884 | 0.87 | BACE1 (0.48) | BACE1BACE2F2GLP1RSCTR | |
| SCHEMBL29680033 | 0.87 | F2 (0.53) | F2NPY1RNPY2RNPY4RGLP1R | |
| SCHEMBL30827584 | 0.87 | BACE1 (0.51) | BACE1BACE2F2NPY1RNPY2R | |
| SCHEMBL30827586 | 0.86 | BACE1 (0.55) | BACE1BACE2F2GLP1RSCTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367097-A1 | COMPOSITIONS AND FORMULATIONS FOR USE OF A PK INHIBITOR FOR THE PREVENTION, TREATMENT, AND IMPROVEMENT OF SKIN DISEASES, CONDITIONS, AND DISORDERS | DERMBIONT INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250228822-A1 | COMPOSITIONS AND FORMULATIONS FOR USE OF A PK INHIBITOR FOR THE PREVENTION, TREATMENT, AND IMPROVEMENT OF SKIN DISEASES, CONDITIONS, AND DISORDERS | DERMBIONT, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12290506-B2 | Compositions and formulations for use of a PK inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders | DERMBIONT, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250127700-A1 | METHODS OF TREATING HYPERPIGMENTATION DISORDERS | DERMBIONT INC (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4525862-A1 | COMPOSITIONS AND FORMULATIONS FOR USE OF A PK INHIBITOR FOR THE PREVENTION, TREATMENT, AND IMPROVEMENT OF SKIN DISEASES, CONDITIONS, AND DISORDERS | Dermbiont, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119497614-A | Compositions and formulations for preventing, treating and ameliorating skin diseases, conditions and disorders using PK inhibitors | 德慕拜昂生物科技公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20240293368-A1 | COMPOSITIONS AND FORMULATIONS FOR USE OF A PK INHIBITOR FOR THE PREVENTION, TREATMENT, AND IMPROVEMENT OF SKIN DISEASES, CONDITIONS, AND DISORDERS | DERMBIONT, INC. | 2024-09-05 | — | — | US | disclosed |
| WO-2023225373-A1 | COMPOSITIONS AND FORMULATIONS FOR USE OF A PK INHIBITOR FOR THE PREVENTION, TREATMENT, AND IMPROVEMENT OF SKIN DISEASES, CONDITIONS, AND DISORDERS | DERMBIONT, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367097-A1 | COMPOSITIONS AND FORMULATIONS FOR USE OF A PK INHIBITOR FOR THE PREVENTION, TREATMENT, AND IMPROVEMENT OF SKIN DISEASES, CONDITIONS, AND DISORDERS | SERPINB1, CUTA, PNPO | BACE1 2146/4885BACE2 3134/4885F2 1021/4885 |
| US-20250228822-A1 | COMPOSITIONS AND FORMULATIONS FOR USE OF A PK INHIBITOR FOR THE PREVENTION, TREATMENT, AND IMPROVEMENT OF SKIN DISEASES, CONDITIONS, AND DISORDERS | SERPINB1, CUTA, PNPO | BACE1 2146/4885BACE2 3134/4885F2 1021/4885 |
| US-12290506-B2 | Compositions and formulations for use of a PK inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders | SERPINB1, CUTA, PNPO | BACE1 2146/4885BACE2 3134/4885F2 1021/4885 |
| US-20240293368-A1 | COMPOSITIONS AND FORMULATIONS FOR USE OF A PK INHIBITOR FOR THE PREVENTION, TREATMENT, AND IMPROVEMENT OF SKIN DISEASES, CONDITIONS, AND DISORDERS | SERPINB1, CUTA, PNPO | BACE1 2146/4885BACE2 3134/4885F2 1021/4885 |
| US-20250127700-A1 | METHODS OF TREATING HYPERPIGMENTATION DISORDERS | TYR, ADH1B, ALDH1A2 | BACE1 4667/4885BACE2 3521/4885F2 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.